Isocitrate dehydrogenase (IDH)6,7 mutation status is a key genetic characteristic used to inform the prognosis and treatment of glioma patients.3,4,5,7,8 PsP affects both IDH mutant and wild-type glioma patients but has been poorly characterized in IDH mutant patients. Here, IDH3A is linked to central nervous system cancer.